Continuous prednisolone versus conventional prednisolone with VMCP-interferon-α2b as first-line chemotherapy in elderly patients with multiple myeloma

British Journal of Haematology

Volumn 131, Issue 3, 2005, Pages 329-337

  Ludwig, Heinz ^a   Spicka, Ivan ^b   Klener, Pavel ^b   Greil, Richard ^c   Adam, Zdenek ^d   Gisslinger, Heinz ^e   Tarkovács, Gábor ^f   Linkesch, Werner ^g   Maniatis, Alice ^h   Morant, Rudolf ⁱ   Drach, Johannes ^e   Kuhn, Ingrid ^j   Schuster, Judith ^a   Hinke, Axel ^k  

^a WILHELMINEN HOSPITAL   (Austria)

^b CHARLES UNIVERSITY   (Czech Republic)

^c University Hospital Salzburg   (Austria)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h UNIVERSITY OF PATRAS   (Greece)

ⁱ Tumor Center ZeTuP   (Switzerland)

^j Medical University of Vienna ^*  (Austria)

^k WiSP Research Institute   (Germany)

more..

Author keywords

Continuous prednisolone; Elderly patients; Multiple myeloma; Randomised trial; VMCP interferon therapy

Indexed keywords

ALPHA2B INTERFERON; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; MELPHALAN; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT; GLUCOCORTICOID; PREDNISONE; VMCP PROTOCOL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DYSPNEA; FEMALE; HAZARD ASSESSMENT; HEART DISEASE; HUMAN; HYPERGLYCEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZATION; RISK FACTOR; VOMITING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERFERON ALFA-2B; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PREDNISOLONE; PREDNISONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 33644807542     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05779.x     Document Type: Article

References (25)

1. Alexanian R. Dimopoulos M.A. Delasalle K. Barlogie B. (1992) Primary dexamethasone treatment of multiple myeloma. Blood, 80, 887 890.
2. Berenson J.R. Crowley J.J. Grogan T.M. Zangmeister J. Briggs A.D. Mills G.M. Barlogie B. Salmon S.E. (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood, 99, 3163 3168.
3. Blade J. Munoz M. Fontanillas M. San Miguel J. Alcala A. Maldonado J. Besses C. Moro M.J. Garcia-Conde J. Rozman C. Montserrat E. Estape J. (1996) Treatment of multiple myeloma in elderly people: long-term results in 178 patients. Age and Ageing, 25, 357 361.
4. Blade J. Samson D. Reece D. Apperley J. Bjorkstrand B. Gahrton G. Gertz M. Giralt S. Jagannath S. Vesole D. (1998a) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115 1123.
5. Blade J. Fernandez-Llama P. Bosch F. Montoliu J. Lens X.M. Montoto S. Cases A. Darnell A. Rozman C. Montserrat E. (1998b) Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Archives of Internal Medicine, 158, 1889 1893.
6. Bruno B. Rotta M. Giaccone L. Massaia M. Bertola A. Palumbo A. Boccadoro M. (2004) New drugs for treatment of multiple myeloma. Lancet Oncology, 5, 430 442.
7. Cox D.R. (1972) Regression models and life tables. Journal of the Royal Statistical Society (B), 34, 187 202.
8. Durie B.G. Salmon S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer, 36, 842 854.
9. Durie B.G. Kyle R.A. Belch A. Bensinger W. Blade J. Boccadoro M. Child J.A. Comenzo R. Djulbegovic B. Fantl D. Gahrton G. Harousseau J.L. Hungria V. Joshua D. Ludwig H. Mehta J. Morales A.R. Morgan G. Nouel A. Oken M. Powles R. Roodman D. San Miguel J. Shimizu K. Singhal S. Sirohi B. Sonneveld P. Tricot G. Van Ness B Scientific Advisors of the International Myeloma Foundation (2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 4, 379 398.
10. Durie B.G. Jacobson J. Barlogie B. Crowley J. (2004) Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. Journal of Clinical Oncology, 22, 1857 1863.
11. Fritz E. Ludwig H. (2000) Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Annals of Oncology, 11, 1427 1436.
12. Greipp P.R. San Miguel J. Durie B.G. Crowley J.J. Barlogie B. Blade J. Boccadoro M. Child J.A. Harousseau J.L. Kyle R.A. Lahuerta J.J. Ludwig H. Morgan G. Powles R. Shimizu K. Shustik C. Sonneveld P. Tosi P. Turesson I. Westin J (2005) An International Staging System (ISS) for multiple myeloma. Journal of Clinical Oncology, 23, 3412 3420.
13. Hideshima T. Bergsagel P.L. Kuehl W.M. Anderson K.C. (2004) Advances in biology of multiple myeloma: clinical applications. Blood, 104, 607 618.
14. Kaplan E.L. Meier P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457 481.
15. Ludwig H. Cohen A.M. Polliack A. Huber H. Nachbaur D. Senn H.J. Morant R. Eckhardt S. Gunczler P. Seewann H.L. Schüller J. Rhyner K. Cavalli F. Fritz E. (1995) Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Annals of Oncology, 5, 467 476.
16. Ludwig H. Durie B.G.M. Rasmussen E. Crowley J., on behalf of the International Myeloma Working Group (2004) Survival in multiple myeloma correlates with patient's age and this is linked to higher stage at presentation but not to prognostic parameters reflecting the biology of the myeloma clone. Blood, 104 (Suppl. 1 1491 3842.
17. Myeloma Trialists' Collaborative Group (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. British Journal of Haematology, 113, 1020 1034.
18. Palmer M. Belch A. Hanson J. Brox L. (1988) Dose intensity of melphalan and prednisone in multiple myeloma. Journal of the National Cancer Institute, 80, 414 418.
19. Palumbo A. Bringhen S. Petrucci M.T. Musto P. Rossini F. Nunzi M. Lauta V.M. Bergonzi C. Barbui A. Caravita T. Capaldi A. Pregno P. Guglielmelli T. Grasso M. Callea V. Bertola A. Cavallo F. Falco P. Rus C. Massaia M. Mandelli F. Carella A.M. Pogliani E. Liberati A.M. Dammacco F. Ciccone G. Boccadoro M. (2004) Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomised controlled trial. Blood, 104, 3052 3058.
20. Peto R. Peto J (1972) Asymptotically efficient rank invariation test procedures (with discussion). Journal of the Royal Statistical Society (B), 135, 185 207.
21. Richardson P.G. Barlogie B. Berenson J. Singhal S. Jagannath S. Irwin D. Rajkumar S.V. Srkalovic G. Alsina M. Alexanian R. Siegel D. Orlowski R.Z. Kuter D. Limentani S.A. Lee S. Hideshima T. Esseltine D.L. Kauffman M. Adams J. Schenkein D.P. Anderson K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609 2617.
22. Salmon S.E. (1998) Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology, 3, 890 896.
23. Singhal S. Mehta J. Desikan R. Ayers D. Roberson P. Eddlemon P. Munshi N. Anaissie E. Wilson C. Dhodapkar M. Zeddis J. Barlogie B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565 1571.
24. Turesson I. Abildgaard N. Ahlgren T. Dahl I. Holmberg E. Hjorth M. Nielsen J.L. Oden A. Seidel C. Waage A. Westin J. Wisloff F. (1999) Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. British Journal of Haematology, 106, 1005 1012.
25. WHO (1979) Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva, Switzerland, pp. 15 22.